Medical Device Network on MSN
Dexcom gives sneak preview of CGM technologies’ long-term health benefits for diabetics
Dexcom will present the full data from several studies at the Advanced Technologies and Treatments for Diabetes conference, ...
BTIG analysts continue to expect growth from Dexcom (Nasdaq:DXCM) after meeting with the company's senior investor relations (IR) officials.
The US FDA has cleared a new “basal insulin dose optimizer” function for the Dexcom G7 15-day continuous glucose monitor (CGM), which is set to launch separately on December 1, 2025. The “Smart Basal” ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results